Shifting the lines against central nervous system disorders

« A disruptive technology, which can be applied in the treatment of numerous conditions »

> Press releases

THERANEXUS provides 2018 full-year results and update on activities

17/04/2019
Download PDF File (416 Ko)

THERANEXUS announces research collaboration with IRISA using artificial intelligence technologies to enhance therapeutic targeting of neuroglial interactions

09/04/2019
Download PDF File (376 Ko)

THERANEXUS to present new scientific data on drug candidate THN201 at AD/PD 2019, the 14th conference on Alzheimer's and Parkinson's diseases

26/03/2019
Download PDF File (377 Ko)

THERANEXUS announces preliminary results of phase II trial of THN102 on narcolepsy patients

27/02/2019
Download PDF File (296 Ko)

THERANEXUS reports cash position as of 31 December 2018 and provides update on current status of activities

13/02/2019
Download PDF File (395 Ko)

THERANEXUS set to receive €6.2 million in funding from the French Investments for the
Future program, managed by Bpifrance, for the development of Neurolead,
its new lead generation platform targeting neuro-glia interactions

29/01/2019
Download PDF File

Theranexus announces appointment of Jérôme Martinez to its Board of Directors
13/12/2018
Download PDF File (370 Ko)

Theranexus September 30th cash position and business update
09/11/2018
Download PDF File (369 Ko)

Theranexus announces inclusion of last patient in phase II trial of drug candidate THN102 on narcolepsy patients

29/10/2018
Download PDF File (371 Ko)

Theranexus plans to extend its phase 2 pipeline with a third program

15/10/2018
Download PDF File (382 Ko)